UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
|
Filed by the Registrant
|
|
|
☒ |
|
|
|
|
Filed by a Party other than the Registrant
|
|
|
☐ |
|
|
|
Check the appropriate box:
| ☐ |
|
|
Preliminary Proxy Statement
|
||
| ☐ |
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
||
| ☐ |
|
|
Definitive Proxy Statement
|
||
| ☒ |
|
|
Definitive Additional Materials
|
||
| ☐ |
|
|
Soliciting Material Pursuant to § 240.14a-12
|
|
Rani Therapeutics Holdings, Inc.
|
|
(Name of Registrant as Specified In Its Charter)
|
|
|
|
|
|
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
|
Payment of Filing Fee (Check all boxes that apply):
| ☒ |
|
|
No fee required.
|
| ☐ |
|
|
Fee paid previously with preliminary materials
|
| ☐ |
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
